Recent achievements include:

• The development of the enhanced liver fibrosis (ELF) blood test by Professor William Rosenberg and colleagues. ELF detects pre-symptomatic stages of liver fibrosis and has been awarded approval by both the FDA and NICE. ELF has had a major impact in reducing unnecessary hospital referrals, clinical investigations, and treatment.
• Dr Rishi Gupta and Professor Maddy Noursadeghi used a computational approach to discover eight blood transcriptomic biomarkers that can be used for tuberculosis (TB) screening. These biomarkers can be used to identify people who are asymptomatically infected with TB but will go on to become symptomatic. It is hoped that future development of a blood test based on these biomarkers could reduce the impact and spread of TB.
• We are a funder of the EMINENT Experimental Medicine consortium which is coordinated by UCL and led by Professor Rachel Chambers. The EMINENT consortium is a unique collaborative network funded by the Medical Research Council (MRC), matched in-kind by GlaxoSmithKline (GSK). The EMINENT consortium consists of five universities (UCL, University of Cambridge, University of Glasgow, University of Newcastle, Imperial College London) and three BRC’s (UCLH, Imperial and Cambridge). The collaboration is supported by a BRC funded clinical fellow at each site, Dr Puja Mehta is the EMINENT fellow at UCL. The EMINENT consortium has unprecedented access to GSK’s unlicensed clinic-ready asset portfolio to enable acceleration of the development of novel therapies for patients in under-served disease areas such as autoimmunity and tissue injury and fibrosis.